Kiniksa Pharmaceuticals, Ltd. (KNSA) Misses Q3 EPS by 19c

Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) reported Q3 EPS of ($0.18), $0.19 worse than the analyst estimate of $0.01. Revenue for the quarter came in at $112.21 million versus the consensus estimate of $110.29 million.

For earnings history and earnings-related data on Kiniksa Pharmaceuticals, Ltd. (KNSA) click here.

You May Also Be Interested In

• Summit Therapeutics (SMMT) Reiterated at Market Outperform by Citizens
• Meta Platforms Inc. (META) PT Raised to $875 at Piper Sandler
• JPMorgan Downgrades Thai Union Group PCL (TU:TB) (TUFBY) to Underweight